In a nutshell This trial is investigating the effects of AVD [doxorubicin (Adriamycin), vinblastine (Velban), and dacarbazine (DTIC)] with brentuximab vedotin (Adcetris) induction chemotherapy, plus nivolumab (Opdivo) for Hodgkin lymphoma (HL). The main outcome to be measured is survival without cancer worsening 3 years after treatment. The details...
Read MoreCurrent stage-Stage II (Early) Posts on Medivizor
Evaluating outcomes after radiotherapy and PET/CT scanning for patients with follicular lymphoma
In a nutshell This study evaluated the outcomes of patients with localized (cancer has not spread to other parts of the body) early-stage follicular lymphoma (FL) after positron emission tomography/computed tomography (PET/CT) scanning. This study concluded that radiotherapy is a highly effective treatment for these patients. Some background FL is one...
Read MoreLong-term outcomes of radioimmunotherapy in patients with follicular lymphoma
In a nutshell This study investigated the long-term outcomes of radioimmunotherapy following first-line (primary) R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) in previously untreated patients with advanced-stage follicular lymphoma (FL). This study concluded that this treatment approach is effective and well-tolerated in...
Read MoreDoes radiotherapy improve outcomes for patients with primary breast diffuse large B-cell lymphoma?
In a nutshell This study evaluated the impact of radiotherapy on the outcomes of rituximab (Rituxan)-treated patients with primary breast diffuse large B-cell lymphoma. This study concluded that radiotherapy has significant therapeutic benefits for these patients. Some background Primary breast diffuse large B-cell lymphoma (DLBCL) is a rare type of...
Read MoreComparing obinutuzumab and rituximab in first-line chemotherapy regimens for follicular lymphoma
In a nutshell This study investigated the safety and effectiveness of obinutuzumab (Gazyva) versus rituximab (Rituxan) plus chemotherapy for previously untreated follicular lymphoma. This study concluded that obinutuzumab improved survival outcomes compared to rituximab. Some background Follicular lymphoma is the most common type of...
Read MoreWhat are the outcomes for advanced HL patients receiving intensified BEACOPP chemotherapy after ABVD chemotherapy?
In a nutshell This study investigated the outcomes of advanced-stage classical Hodgkin’s lymphoma (HL) patients treated with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy followed by escalated (higher dose) BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) chemotherapy...
Read MoreTreatment options for elderly patients with early stage Hodgkin lymphoma
In a nutshell This study reviewed the treatments for elderly patients with early-stage Hodgkin lymphoma. The study concluded that combined chemotherapy and radiation therapy has the best outcomes, however the use of radiation therapy is not ideal. Some background Hodgkin lymphoma (HL) is generally considered a curable disease. However, outcomes in...
Read MoreDifferent types of treatment for patients with early stage mantle cell lymphoma
In a nutshell This study looked at the outcomes of different types of initial treatment for patients diagnosed with early stage mantle cell lymphoma. The study concluded that a reduced intensity treatment approach is worthwhile for patients with early stage mantle cell lymphoma. Some background Mantle cell lymphoma (MCL) is a type of non-Hodgkin...
Read MoreA review of chemotherapy alone or chemotherapy plus radiation therapy to treat adult patients with Hodgkin lymphoma
In a nutshell This paper is a review of the effectiveness of chemotherapy alone or chemotherapy plus radiotherapy for treating adult patients with early stage Hodgkin lymphoma. The review concluded that, for the same chemotherapy regimen, RT may increase progression free survival, but has little effect on overall survival for patients. Some background...
Read MoreLooking for patients with relapsed B-cell non-Hodgkin’s lymphoma to test the effectiveness of a copanlisib and rituximab combination treatment
In a nutshell This phase 3 clinical trial will evaluate the safety and effectiveness of a copanlisib (BAY 80-6946) and rituximab (Rituxan) combination in treating patients with relapsed indolent B-cell non-Hodgkin’s lymphoma (iNHL). The primary outcome will be measured by time to disease progression. The details Copanlisib is an inhibitor of...
Read MoreLooking for patients with cutaneous T-cell lymphoma to test topical SGX301 (synthetic hypericin)
In a nutshell This phase 3 clinical trial will test the effectiveness of topical SGX301 (synthetic hypericin) in treating patch or plaque phase mycosis fungoides. The primary outcome will be measured by the treatment response. The details Mycosis fungoides cutaneous T-cell lymphoma (CTCL), is a cancer of T-cells involving the skin. During the...
Read MoreLooking for patients with HIV-associated Hodgkin’s lymphoma to test an immunotherapy
In a nutshell This phase 1/2 clinical trial will test the safety and effectiveness of brentuximab vedotin (SGN-35) in treating HIV-associated Hodgkin’s lymphoma. The primary outcome will be measured by the maximum tolerated dose (due to side effects) and the time to disease progression. The details Brentuximab vedotin is a therapy that...
Read More
